Virtual Celebration Platform Presentations V2

2020 PLATFORMS

Disease Assessment and Management (DAM)
Disease Modifying Therapies (DMT)
Psychosocial: Cognition (PSY)
Rehabilitation (RHI)

DISEASE ASSESSMENT AND MANAGEMENT

ID: DAM01

International Registry Tracking Pregnancy Outcomes in Women Treated with Dimethyl Fumarate

Maria Houtchens,¹ Kerstin Hellwig,² David Rog,³ Christopher McGuigan,⁴ Denise R. Bruen,⁵ Kun Chen,⁶ Xiaomei Peng,⁶ Cynthia C. Jones⁶
¹Brigham and Women’s Hospital, Boston, MA; ²University of Bochum, Neurological Clinic, Bochum, Germany; ³Manchester Centre for Clinical Neurosciences, Salford, United Kingdom; ⁴Department of Neurology, St. Vincent’s University Hospital, Dublin, Ireland; ⁵Department of Neuroscience, University of Virginia Health, Charlottesville, VA; ⁶Biogen, Cambridge, MA

ID: DAM02

Menarche and Relapses in Girls with Pediatric Multiple Sclerosis

Kristen M. Krysko,¹ Michael Waltz,² Tanuja Chitnis,³ Bianca Weinstock-Guttman,⁴ Greg Aaen,⁵ Leslie Benson,⁶ Mark Gorman,⁶ Yolanda Harris,⁷ Lauren B. Krupp,⁸ Timothy Lotze,⁹ Soe Mar,¹⁰ Manikum Moodley,¹¹ Jayne Ness,¹² Mary Rensel,¹³ Moses Rodriguez,¹⁴ John Rose,¹⁵ Alice Rutatangwa,¹ Teri Schreiner,¹⁶ Emmanuelle Waubant,¹ T. Charles Casper,² Jennifer S. Graves17,¹⁸
¹Neurology, University of California San Francisco, San Francisco, CA; ²Pediatrics, University of Utah, Salt Lake City, UT; ³Pediatric Neurology, Massachusetts General Hospital, Boston, MA; ⁴Neurology, State University of New York at Buffalo, Buffalo, NY; ⁵Pediatrics, Loma Linda University, San Bernardino, CA; ⁶Neurology, Boston Children’s Hospital, Boston, MA; ⁷Nursing, University of Alabama at Birmingham, Birmingham, AL; ⁸Neurology, NYU Langone Medical Center, New York, NY; ⁹Neurology, Texas Children’s Hospital, Houston, TX; ¹⁰Neurology, Washington University in Saint Louis, St. Louis, MO; ¹¹Pediatrics and Neurology, Dell Children’s Hospital, University of Texas, Austin,TX; ¹²Pediatrics, University of Alabama at Birmingham, Birmingham, AL; ¹³Neurology, Cleveland Clinic, Cleveland, OH; ¹⁴Neurology, Mayo Clinic, Rochester, MN; ¹⁵Neurology, University of Utah, Salt Lake City, UT; ¹⁶Neurology and Pediatrics, University of Colorado, Aurora, CO; ¹⁷Neurosciences, University of California San Diego, San Diego, CA; ¹⁸Neurology, University of California San Diego, La Jolla, CA

ID: DAM03

Complexity of Aging with Multiple Sclerosis: Graceful Concessions or Kicking and Screaming?

Emma V. Richardson, Robert W. Motl
Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL

ID: DAM04

Serum Glial Fibrillary Acidic Protein Is Elevated in a Subset of Neuromyelitis Optica Patients and Associated with Increased Risk of Attacks

Hans-Peter Hartung,¹ Orhan Aktas,² Michael A. Smith,³ William Rees,³ Kazuo Fujihara,⁴ Friedemann Paul,⁵ Romain Marignier,⁶ Jeffrey L. Bennett,⁷ Ho Jin Kim,⁸ Brian Weinshenker,⁹ Sean J. Pittock,¹⁰ Dean Wingerchuk,¹¹ Gary Cutter,¹² Ari Green,¹³ Maureen A. Mealy,³ Jorn Drappa,³ Gerard Barron,³ Soraya Madani,³ Liangwei Wang,³ Dewei She,³ Daniel Cimbora,³ John N. Ratchford,³ Eliezer Katz,3 Bruce A.C. Cree¹⁴
¹Department of Neurology, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany; ²Medical Faculty, Heinrich-Heine-University, Dusseldorf, Germany; ³Viela Bio, Gaithersburg, MD; ⁴Department of Multiple Sclerosis Therapeutics, Southern Tohoku Research Institute for Neuroscience (STRINS), Koriyama, Japan; ⁵Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charite – Universitatsmedizin Berlin, Berlin, Germany; ⁶Lyon University Hospital, Lyon, France; ⁷School of Medicine, University of Colorado, Aurora, CO; ⁸Research Institute and Hospital, National Cancer Center, Goyang, Korea, Republic of (South); ⁹Neurology, Mayo Clinic, Rochester, MN; ¹⁰Mayo Clinic, Rochester, MN; ¹¹Neurology, Mayo Clinic Arizona, Scottsdale, AZ; ¹²Biostatistics, University of Alabama at Birmingham, Birmingham, AL; ¹³Department of Neurology and Department of Ophthalmology, UCSF Weill Institute for Neurosciences, San Francisco, CA; ¹⁴Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA

ID: DAM05

Machine Learning Algorithms Applied to Visual Metrics to Classify Demyelinating Disease Diagnosis in Children

Beyza Ciftci,¹ Can Kavaklioglu,² Lauren Erdman,¹ Anna Goldenberg,^3,4,5,6 Tara Berenbaum,⁷ Tara Feltham,⁷ Fiona Costello,⁸ Jean Mah,⁹ Arun Reginald,¹⁰ Brenda Banwell,¹¹ Giulia Longoni,¹² E. Ann Yeh¹²
¹Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada; ²Department of Mechanical and Industrial Engineering, Ryerson University, Toronto, ON, Canada; ³Genetics and Genome Biology Lab, The Hospital for Sick Children, Toronto, ON, Canada; ⁴Department of Computer Science, University of Toronto, Toronto, ON, Canada; ⁵Vector Institute, Toronto, ON, Canada; ⁶CIFAR, Toronto, ON, Canada; ⁷Department of Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON, Canada; ⁸Departments of Clinical Neurosciences and Surgery, University of Calgary, Calgary, AB, Canada; ⁹Department of Pediatrics, University of Calgary, Calgary, AB, Canada; ¹⁰Ophthalmology and Vision Sciences, The Hospital for Sick Children, Toronto, ON, Canada; ¹¹Neurology, The Children’s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ¹²Department of Paediatrics, Division of Neurology, The Hospital for Sick Children, Toronto, ON, Canada

ID: DAM06

Updated Recommendations for a Standardized Magnetic Resonance Imaging Protocol for Multiple Sclerosis

Anthony Traboulsee,¹ David Li,¹ Brenda Banwell,² Frederik Barkhof,³ Kathleen Costello,⁴ Peter Damiri,⁵ Scott D. Newsome,⁶ Jiwon Oh,⁷ Friedemann Paul,⁸ Daniel S. Reich,⁹ Mitchell T. Wallin,¹⁰ Jerry S. Wolinsky,¹¹ June Halper,¹² Sarah A. Morrow,¹³ Wim Van Hecke,¹⁴ Laura Barlow,¹⁵ Jason Shewchuk,¹⁶ Russell Shinohara,¹⁷ Amy Verrinder,¹⁸ Micki Maes,¹⁸ Patrick Quarterman,¹⁹ Kim van de Ven,²⁰ Shivraman Giri,²¹ Lori Saslow,²² CMSC MRI Guidelines Working Group ¹The University of British Columbia, Vancouver, BC, Canada; ²Neurology, The Children’s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;³Institutes of Neurology and Healthcare Engineering, University College London, London, United Kingdom; ⁴National MS Society, New York, NY; ⁵Multiple Sclerosis Association of America, Cherry Hill, NJ; ⁶Neurology, Johns Hopkins University School of Medicine, Baltimore, MD; ⁷University of Toronto, Toronto, ON, Canada; ⁸Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charite – Universitatsmedizin Berlin, Berlin, Germany; ⁹Translational Neuroradiology Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD; ¹⁰Washington, DC, VA Medical Center, MS Center of Excellence, Washington, DC; ¹¹University of Texas Health Science Center at Houston (UTHealth), Houston, TX; ¹²CEO-CMSC, Hackensack, NJ; ¹³Western University, London, ON, Canada; ¹⁴Icometrix, Leuven, Belgium; ¹⁵UBC MRI Research Centre, University of British Columbia, Vancouver, BC, Canada; ¹⁶Vancouver General Hospital, Vancouver, BC, Canada; ¹⁷University of Pennsylvania, Philadelphia, PA; ¹⁸Cortechs Labs, Inc, San Diego, CA; ¹⁹GE Healthcare, New York, NY; ²⁰Philips Healthcare, Eindhoven, Netherlands; 21Siemens Healthineers, Boston, MA; 22Consortium of Multiple Sclerosis Centers, Hackensack, NJ

DISEASE-MODIFYING THERAPY

ID: DMT01

Comparative Effectiveness of Switching from Natalizumab to a Moderate- Versus High-Efficacy Disease-Modifying Therapy in Clinical Practice

Carrie M. Hersh,¹ Haleigh Harris,² Devon Conway,³ Le H. Hua¹ ¹Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV; ²Las Vegas, NV; ³Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH

ID: DMT02

Yearly Efficacy and Safety Outcomes Over 4 Years After Last Alemtuzumab Course in Pooled CAREMS I and II Patients by Number of Additional Courses Received Through Year 9

Regina Berkovich,^1,2 Raed Alroughani,³ Ann D. Bass,⁴ Aaron L. Boster,⁵ Giancarlo Comi,⁶ Ho Jin Kim,⁷ Volker Limmroth,⁸ Jan Lycke,⁹ Richard A.L. Macdonell,¹⁰ Sven Schippling,¹¹ Basil Sharrack,¹² Mar Tintoré,¹³ Anthony Traboulsee,¹⁴ Patrick Vermersch,¹⁵ Heinz Wiendl,¹⁶ Tjalf Ziemssen,¹⁷ Nadia Daizadeh,¹⁸ Alan Jacobs,¹⁸ Elizabeth M. Poole,¹⁸ Barry A. Singer,¹⁹ on behalf of the CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators
¹Keck School of Medicine, University of Southern California, Los Angeles, CA; ²Regina Berkovich, MD, PhD, Inc, West Hollywood, CA; ³Amiri Hospital, Sharq, Kuwait; ⁴Neurology Center of San Antonio, San Antonio, TX; ⁵Boster MS Center, Columbus, OH; ⁶University Vita-Salute San Raffaele, Milan, Italy; ⁷Research Institute and Hospital, National Cancer Center, Goyang, Korea, Republic of (South); ⁸Klinik für Neurologie und Palliativmedizin, Cologne, Germany; ⁹Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden; ¹⁰Austin Health and Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia; ¹¹University Hospital Zürich and University of Zürich, Zürich, Switzerland; ¹²NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals, University of Sheffield, Sheffield, United Kingdom; ¹³University Hospital Vall d’Hebron, Barcelona, Spain; ¹⁴The University of British Columbia, Vancouver, BC, Canada; ¹⁵University of Lille, INSERM U995, CHU Lille, Lille, France; ¹⁶Department of Neurology, University of Münster, Münster, Germany; ¹⁷Center for Clinical Neuroscience, Carl Gustav Carus University Hospital, Dresden, Germany; ¹⁸Sanofi, Cambridge, MA; ¹⁹The MS Center for Innovations in Care, Missouri Baptist Medical Center, St Louis, MO

ID: DMT03

Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients with Relapsing Multiple Sclerosis: Phase 3 ASCLEPIOS I and II Trials

Anne H. Cross,¹ Ludwig Kappos,² Amit Bar-Or,³ Jeffrey A. Cohen,⁴ Giancarlo Comi,⁵ Jorge Correale,⁶ Patricia K. Coyle,⁷ Jerome de Seze,⁸ David Leppert,⁹ Xavier Montalban,^10,11 Krzysztof W. Selmaj,¹² Heinz Wiendl,¹³ Cecile Kerloeguen,¹⁴ Roman Willi,¹⁴ Bingbing Li,¹⁵ Algirdas Kakarieka,¹⁴ Davorka Tomic,¹⁴ Alexandra Goodyear,¹⁵ Ratnakar Pingili,¹⁵ Dieter A. Haering,¹⁴ Krishnan Ramanathan,¹⁴ Martin Merschhemke,¹⁴ Stephen L. Hauser¹⁶ ¹Department of Neurology, Division of Neuroimmunology, Washington University School of Medicine, St Louis, MO; ²Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital of Basel, Basel, Switzerland; ³Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ⁴Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH; ⁵University Vita-Salute San Raffaele, Milan, Italy; ⁶Institute for Neurological Research Dr. Raul Carrea, Buenos Aires, Argentina; ⁷Stony Brook University, Stony Brook, NY; ⁸University Hospital of Strasbourg, Strasbourg, France; ⁹Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland; ¹⁰Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona, Spain; ¹¹St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada; ¹²Department of Neurology, Medical Academy of Lodz, Lodz, Poland; 13Department of Neurology, University of Münster, Münster, Germany; ¹⁴Novartis Pharma AG, Basel, Switzerland; ¹⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ; ¹⁶University of California, San Francisco, San Francisco, CA

ID: DMT04

Treatment-Emergent Adverse Events Occurring Early in the Treatment Course of Cladribine Tablets in Two Phase 3 Trials in Multiple Sclerosis

Jiwon Oh,¹ Bryan Walker,² Gavin Giovannoni,³ Dominic Jack,⁴ Fernando Dangond,⁵ Axel Nolting,⁴ Julie Aldridge,⁵ Lori Lebson,⁶ Thomas P. Leist⁷
¹Keenan Research Center for Biomedical Sciences, St. Michaels Hospital, Toronto, ON, Canada; ²Neurological Department, Duke University School of Medicine, Durham, NC; ³Blizard Institute of Cell and Molecular Science, London, United Kingdom; ⁴Merck KGaA, Darmstadt, Germany; ⁵EMD Serono, Inc, Billerica, MA; ⁶EMD Serono, Inc, Rockland, MA; ⁷Jefferson University Hospital, Philadelphia, PA

PSYCHOSOCIAL: COGNITION

ID: PSY01

A Mindfulness Group Intervention in Newly Diagnosed Persons with Multiple Sclerosis: A Pilot Study

Sarah A. Morrow,¹ Nancy Vording,¹ Jordan Ward,¹ Courtney S. Casserly,² Heather Rosehart,³ Arlene Macdougall⁴
¹Clinical Neurological Sciences, London Health Sciences Centre, London, ON, Canada; ²Clinical Neurological Sciences, Western University, London, ON, Canada; ³Clinical Neurological Sciences, University of Western Ontario, London Health Sciences Center, London, ON, Canada; ⁴Psychiatry and Epidemiology & Biostatistics, St. Joseph’s Health Care, Parkwood Institute, London, ON, Canada

ID: PSY02

Effects of Weekly Participation in a Wellness Program on Self-Reported Measures for People Living with Multiple Sclerosis: A 3-Year Analysis

Brian Hutchinson,¹ John Schafer,² Lacey Sayre,³ Tiffany Malone³ ¹Multiple Sclerosis Achievement Center, Dignity Health, Sacramento, CA; ²Mercy MS Center, Carmichael, CA; ³Multiple Sclerosis Achievement Center, Dignity Health, Citrus Heights, CA

ID: PSY03

Examining Multilevel Environmental Correlates of Physical Activity Among Older Adults with Multiple Sclerosis

Stephanie L. Silveira, Jessica F. Baird, Robert W. Motl
Physical Therapy, University of Alabama at Birmingham, Birmingham, AL

ID: PSY04

Effect of Nabiximols Cannabinoid Oromucosal Spray on Depressive Symptoms, Suicidality, and Cognition in Patients with Multiple Sclerosis

John DeLuca,¹ Dawn Langdon,² Joris Berwaerts,³ Joanne Wagner³
¹Kessler Foundation, West Orange, NJ; ²Department of Psychology, Clinical, Health and Social Psychology, Royal Holloway, University of London, Egham, United Kingdom; ³Greenwich Biosciences, Inc, Carlsbad, CA

ID: PSY06

Multiple Sclerosis Management: Predicting Disease Trajectory of Multiple Sclerosis on Multidimensional Data Including Digital Cognitive Assessments and Patient-Reported Outcomes Using Machine Learning Techniques

Mark Gudesblatt,¹ Jared Srinivasan,¹ Olivia Kaczmarek,¹ Daniel Kantor,² Daniel Golan,³ Myassar Zarif,¹ Barbara Bumstead,¹ Marijean Buhse,¹ Lori Fafard,¹ Timothy Fratto,⁴ Jeffrey Wilken,⁴ Cynthia Sullivan,⁵ Glen Doniger⁶
¹South Shore Neurologic Associates, Patchogue, NY; ²Florida Atlantic University, Boca Raton, FL; ³Rapparport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; ⁴Washington Neuropsychology Research Group, Washington, DC; ⁵Nursing, State University of New York at Stony Brook, Stony Brook, NY; ⁶NeuroTrax Corp, Modiin, Israel

REHABILITATION

ID: RHI01

Significant Structural Neuroplasticity Changes Can Follow Physical Behavioral Change Therapy for Multiple Sclerosis

Victor W. Mark,¹ Brent M. Womble,² Gitendra Uswatte,² David M. Morris,³ Mary H. Bowman,² Staci McKay,² Edward Taub²
¹Physical Medicine and Rehabilitation, University of Alabama at Birmingham (UAB), Birmingham, AL; ²Psychology, UAB, Birmingham, AL; ³Physical Therapy, UAB, Birmingham, AL

ID: RHI02

A New Look at the Symbol Digit Modalities Test in Multiple Sclerosis and Disabilities

Yilan Liu,¹ Victor W. Mark,² Sean Bowman,¹ Razeen M. Mahmud,¹ Janet Niemeier,¹ Stacey S. Cofield³
¹University of Alabama at Birmingham (UAB), Birmingham, AL; ²Physical Medicine and Rehabilitation, UAB, Birmingham, AL; ³Biostatistics, UAB, Birmingham, AL

ID: RHI03

Creating a Yoga Program as Part of a Comprehensive Multiple Sclerosis Care Model

Sandra Chapman, Ruth Almen, Carrie M. Hersh, Le H. Hua
Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV

ID: RHI04

Feasibility of “Sit Less, Move More”: An Intervention for Reducing Sedentary Behavior Among African Americans with Multiple Sclerosis

Jessica F. Baird,¹ Jeffer E. Sasaki,² Brian M. Sandroff,¹ Gary Cutter,³ Robert W. Motl¹
¹Physical Therapy, University of Alabama at Birmingham, Birmingham, AL; ²Department of Sports Sciences, Universidade Federal do Triangulo Mineiro, Bairro Tutunas, Brazil; ³Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, AL

ID: RHI05

The Effect of Aerobic Fitness on Physical and Cognitive Function and Brain Volume in Older Adults with Multiple Sclerosis

Jessica F. Baird,¹ Marcas Bamman,² Cynthia Brown,² John R. Rinker,³ Robert W. Motl¹
¹Physical Therapy, University of Alabama at Birmingham (UAB), Birmingham, AL; ²UAB, Birmingham, AL; ³Neurology, UAB, Birmingham, AL

ID: RHI06

Functional Electrical Stimulation Cycling Exercise Reduces Lower Limb Strength Asymmetry in Persons with Multiple Sclerosis

John W. Farrell III,¹ Thomas Edwards,² Robert W. Motl,³ Lara A. Pilutti¹
¹Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON, Canada; ²School of Human Kinetics, University of Ottawa, Ottawa, ON, Canada; ³Physical Therapy, University of Alabama at Birmingham, Birmingham, AL